Author name | Age/Gender | Type of anticoagulant | Outcome | Complications | ||
---|---|---|---|---|---|---|
Prior to VTE | VTE treatment (during hospitalization) | Upon discharge | ||||
Kenyani Davis | 34 M | N/A | N/A | NOAC | Recovery or discharge | N/A |
Aoi et al | 70 F | Heparin | IV Heparin | N/A | Death | Cardiac arrest |
Brüggemann et al | 57 M | LMWH (nadroparin) | LMWH (tinzaparin) | N/A | Recovery or discharge | Ischemic stroke |
Colombo et al | 73 F | LMWH (enoxaparin) | LMWH (enoxaparin) | NOAC | Recovery or discharge | Obstructive shock |
Delcros et al | 31 M | LMWH (enoxaparin) | LMWH (enoxaparin) | LMWH (enoxaparin) | Recovery or discharge | N/A |
Fiorini et al | 26 F | N/A | LMWH (enoxaparin) | NOAC | Recovery or discharge | N/A |
Haider et al | 46 F | Heparin | LMWH (enoxaparin) | NOAC | Recovery or discharge | N/A |
Kasinathan et al | 20 F | N/A | LMWH (enoxaparin) | LMWH (enoxaparin) | Recovery or discharge | N/A |
Mene-Afejuku et al | 67 M | Heparin | NOAC | NOAC | Recovery or discharge | N/A |
58 F | Heparin | LMWH (enoxaparin) | NOAC | Recovery or discharge | N/A | |
89 F | Heparin | IV Heparin | NOAC | Recovery or discharge | N/A | |
82 F | LMWH (enoxaparin) | LMWH (enoxaparin) | NOAC | Recovery or discharge | N/A | |
Akel et al | 28 F | LMWH (enoxaparin) | tPA, LMWH (enoxaparin) | NOAC | Recovery or discharge | N/A |
52 M | LMWH (enoxaparin) | LMWH (enoxaparin) | NOAC | Recovery or discharge | N/A | |
62 M | N/A | tPA, IV heparin | NOAC | Recovery or discharge | N/A | |
49 M | LMWH (enoxaparin) | LMWH (enoxaparin) | NOAC | Recovery or discharge | N/A | |
59 F | LMWH (enoxaparin) | LMWH (enoxaparin) | NOAC | Recovery or discharge | N/A | |
69 M | Heparin | IV Heparin | NOAC | Recovery or discharge | N/A | |
Fortuzi et al | 52 M | Heparin | IV Heparin | N/A | Death | AKI, Septic shock |
74 F | LMWH (enoxaparin) | LMWH (enoxaparin) | NOAC | Recovery or discharge | N/A | |
31 M | N/A | NOAC | NOAC | Recovery or discharge | N/A | |
Kanso et la | 68 M | LMWH (enoxaparin) | LMWH (enoxaparin) | Warfarin | Recovery or discharge | N/A |
62 M | LMWH (enoxaparin) | LMWH (enoxaparin) | NOAC | Recovery or discharge | N/A | |
Lewis et al | 77 M | NOAC (Apixaban) | LMWH (enoxaparin) | N/A | Death | Multi-system organ failure |
70 M | NOAC (Apixaban) | LMWH (enoxaparin) | NOAC (Apixaban), LMWH (enoxaparin), loaded warfarin | Recovery or discharge | N/A | |
76 M | NOAC (Rivaroxaban) | LMWH (enoxaparin) | NOAC (Rivaroxaban) | Recovery or discharge | N/A | |
80 M | NOAC (Rivaroxaban) | LMWH (enoxaparin) | LMWH (enoxaparin) | Death | N/A | |
92 M | NOAC (Apixaban) | Care withdrawn | Care withdrawn | Death | Left-sided facial droop, left-sided hemiplegia and stroke | |
Manek et al | 66 M | N/A | IV heparin | NOAC (Apixaban) | Recovery or discharge | N/A |
Mangala et al | 55 M | LMWH (enoxaparin) | LMWH (enoxaparin) | NOAC (Apixaban) | Recovery or discharge | aspiration pneumonia |
67 F | LMWH (enoxaparin) | IV heparin | NOAC (Apixaban) | Recovery or discharge | N//A | |
Nelson et al | 61 M | N/A | IV heparin | N/A | Death | Septic shock |
54 M | N/A | tPA, LMWH (enoxaparin) | N/A | Death | N/A. | |
Overstada et al | 55 M | N/A | NOAC (Apixaban) | N/A | Recovery or discharge | N/A |
39 M | N/A | NOAC (Apixaban) | NOAC (Apixaban) | Recovery or discharge | N/A | |
57 M | N/A | NOAC (Apixaban) | NOAC (Apixaban) | Recovery or discharge | N/A | |
55 M | N/A | LMWH (Dalteparin) | LMWH (Dalteparin) | Recovery or discharge | N/A | |
Sakr et al | 66 M | N/A | tPA and IV heparin | N/A | Death | Progressive multi-organ failure |
65 M | N/A | LMWH (enoxaparin) | LMWH | Recovery or discharge | N/A | |
56 M | N/A | LMWH (enoxaparin) | LMWH | Recovery or discharge | N/A | |
41 M | N/A | tPA, VA -ECMO, LMWH (tinzaparine) | LMWH | Recovery or discharge | Ventilator-associated pneumonia, severe hypoxemia. | |
49 M | LMWH (enoxaparin) | LMWH | N/A | Death | Necrotizing pneumonia | |
Salam et al | 36 M | N/A | tPA , LMWH (enoxaparin) | NOAC (Apixaban) | Recovery or discharge | N/A |
Sethi et al | 44 M | N/A | tPA, LMWH (enoxaparin), VA -ECMO | LMWH | Recovery or discharge | Bleeding within the oropharynx |
Singh et al | 69 F | N/A | IV heparin | NOAC (Rivaroxaban) with low dose ASA | Recovery or discharge | N/A |
33 M | N/A | IV heparin | NOAC (Rivaroxaban) | Recovery or discharge | N/A | |
69 F | NOAC (Apixaban) | LMWH | N/A | Undetermined | Massive stroke in the territory of the left middle cerebral artery and clinically deteriorated. | |
Uppuluri et al | 32 M | N/A | LMWH (enoxaparin) | NOAC (Apixaban) | Undetermined | N/A |
VTE: venous thromboembolism, N/A: not available, M: male, F: female, LMWH: low molecular weight heparin, IV: intravenous; NOAC: novel oral anticoagulants, VA-ECMO: venoarterial extracorporeal membrane oxygenation, AKI: acute kidney injury, tPA: tissue plasminogen activator, ASA: acetylsalicylic acid (aspirin)